Kornimate/medical-research-clean huggingface dataset:
post-operative analgesic effects of dexamethasone added to bupivacaine in transversusabdominis plane (tap) block

Conditions: Postoperative Analgesia

Summary: to compare the postoperative analgesic effect of two doses of dexamethasone added to bupivacaine in ultrasound-guided tap block for inguinal hernia repair.

the transverses abdominis plane block (tap block) is a regional anesthesia technique that provides analgesia following abdominal surgery . the tap block significantly reduces pain after open inguinal hernia repair, regardless of whether it is used as a primary anesthesia technique or as a complement to general anesthesia, spinal or local anesthesia . the investigators designed this study to compare the postoperative analgesic effect of two doses of dexamethasone( 4 mg and 8 mg ) added to bupivacaine in ultrasound-guided tap block for inguinal hernia repair.

Eligibility criteria:
inclusion criteria: * patients' age from 18 to 60 years old, * physical status asa i-ii (by the american society of anesthesiologists), * elective unilateral open inguinal hernia repair, * under spinal anesthesia exclusion criteria: * age \ 60, * american society of anesthesiologist (asa)class iii-iv, * known allergy to amino amide local anesthetics, * skin infection and diseases at site of injection. * coagulation disorders, * patients with body mass index (bmi) \> 35 kg/m2, * scrotal hernias,

Keywords: tap block inguinal hernia
visual quality following aspheric intraocular lens (iol) implantation - a comparative clinical study

Conditions: Aphakia; Cataract

Summary: to evaluate visual acuity and quality of vision in participants undergoing cataract surgery with a hoya model 751 intra-ocular lens and to compare the visual results to the common monofocal lens in use.


Eligibility criteria:
inclusion criteria: * senile cataract * patient identified as a candidate for cataract surgery and iol implantation * willing to sign informed consent document approved by the ethical committee * willing to complete all required tests and exams per this protocol exclusion criteria: * amblyopia * history or evidence of any ocular disease that may affect visual acuity * previous ocular surgery, including refraction surgery * ocular anomalies (e.g. microphthalmos, kerataconous) * subjects with greater than 1.0 d of corneal astigmatism * subjects who experience intraoperative complications that could affect postoperative iol centration or tilt

Keywords: aphakia cataract
dbt for smoking cessation in high risk veterans

Conditions: Tobacco Dependence; Suicidal

Summary: individuals prone to suicidality are typically excluded from tobacco cessation interventions even though they are disproportionately likely to smoke, and even though smoking cessation has been linked to improved mood and reduced risk of suicide. this trial enrolls veteran smokers at high risk for suicide, and assigns them to receive either cessation treatment as usual, or a novel treatment that incorporates standard behavioral cessation treatment with dialectical behavior therapy (dbt), an evidence-based treatment for suicide risk.

individuals with behavioral health problems are a significant tobacco-related health disparity group in that they are more likely to use tobacco and evidence disproportionate consequences from their use. cigarette smoking or usage of other nicotine products is strongly associated with symptoms of emotional distress, while cessation is associated with significant reductions in symptoms of anxiety and depression and improved mental health functioning. individuals with who have difficulty managing negative emotions (emotional dysregulation) may be especially vulnerable to tobacco dependence and have particular difficulties with smoking cessation. because cessation studies commonly exclude smokers exhibiting emotional dysregulation (such as recent suicidality and/or acute emotional instability), little extant evidence is available to inform optimal treatment approaches for these smokers. dialectical behavior therapy skills group (dbt-sg) is an evidence-based approach to addressing dysregulation of emotion, teaching skills to help manage emotions more effectively. preliminary empirical work suggests dbt may also be an effective approach to addressing smoking cessation. difficulty managing negative emotions is a common reason for smoking cessation failure, suggesting that group dbt may be an effective intervention for cessation. investigators propose to conduct a pilot treatment study with veterans at risk for suicide as an initial step to developing and evaluating the utility of dbt for smoking cessation in subgroups with high levels of emotion dysregulation. the primary aims of the proposed study are to 1) adapt a 12-week, manualized dbt-based group intervention for smoking cessation (dbt-c); 2) conduct a randomized trial testing whether dbt-c has better smoking cessation outcomes than standard smoking cessation treatment (scct); 3) evaluate whether dbt-c participants have greater improvements on measures of emotion regulation, mood and suicidality than those in the ssct conditions; and 4) examine intervention acceptability and feasibility.

Eligibility criteria:
inclusion criteria: * veteran receiving va healthcare * multiple indicators of elevated suicide risk in 6 month period exclusion criteria: * cognitive impairment * unable to attend virtual intervention
study of xeloxiri regimen for patients with refractory metastatic colorectal cancer

Conditions: Colorectal Cancer

Summary: this is an open-label, single centre, single-arm phase ii study which aims to assess the efficacy and tolerability of triplet combination of capecitabine, oxaliplatin and irinotecan (xeloxiri regimen) in treating patients with refractory metastatic colorectal cancer. clinical data from patients diagnosed with colorectal cancer will be collected and analyzed in this study. the patients' data will be collected and maintained in the division of medical oncology of the department of medicine, queen mary hospital.


Eligibility criteria:
inclusion criteria: * adults ≥ 18 years of age, male or female. * histopathologically or cytologically confirmed adenocarcinoma. * failed ≥ 2 lines of standard therapy which must include a fluoropyrimidine, oxaliplatin and/or irinotecan, administered either as monotherapy or doublets. * ecog performance status 0 to 2. * adequate bone marrow reserve. * absolute neutrophil count \> 1 × 109/l. * total bilirubin \< 3 × the upper limit of the normal range. * life expectancy ≥ 12 weeks. * signed written informed consent form. exclusion criteria: * prior malignant disease other than colorectal cancer within 5 years of study entry. * patients suitable for surgical or locoregional therapies. * patients unable to swallow oral medications. * any evidence of brain metastasis (unless the patient is \>6 months from definitive therapy, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry). * active clinically serious infections (\> grade 2 nci / ctc adverse event version 3.0). * history of allergy to platinum compounds. * patients who have chronic inflammatory bowel disease and/or bowel obstruction. * patients who have severe bone marrow failure. * patients undergoing renal dialysis. * history of hiv infection. * seizure disorder requiring medication (such as steroids or anti-epileptics). * women who are pregnant or breast-feeding, or women of child-bearing potential who are unable or unwilling to practice a highly effective means of contraception. * substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of study results.
double-blinded, randomized, placebo-controlled study evaluating the effect of the probiotic on recurrent urinary tract infection

Conditions: Recurrent Urinary Tract Infection in Adult Women

Summary: urinary tract infections (utis) are the most common bacterial infections in women, with about 50% of women experiencing at least one uti in their lifetime. the main pharmacological treatments of cystitis usually involve the use of antibiotics, in particular quinolones (such as ciprofloxacin and levofloxacin), fosfomycin, second-generation and third-generation cephalosporins, and b-lactam antibiotics associated with b-lactamase inhibitors.

this is a double-blinded, randomized, placebo-controlled, parallel-group study evaluating the effect of the probiotic on recurrent urinary tract infection (uti) in adult women recently treated for uti. primary objective the primary objective is to evaluate the effect of oral supplementation with probiotic on the frequency of uti during six months from start of intervention in adult women with recurrent uti.

Eligibility criteria:
inclusion criteria: 1. willing and able to give informed consent for participation in the study. 2. woman aged 18-50 years old at screening. 3. bmi ≥18 at screening. 4. currently on antibiotic treatment for uti, at the time of screening. antibiotic treatment must stop within three days prior to first ip dose. 5. recurrent uti defined as at least two utis during the last six months or at least three utis during the last 12 months, according to information given by the subject. 6. able and willing to comply with the restrictions defined for the the study period (see section 10.6). 7. access to bank id and ability to use the e-health platform (i.e. internet access). 8. ability to understand and comply with the requirements of the study, as judged by the investigator. exclusion criteria: 1. postmenopausal (defined as 12 months of amenorrhoea). 2. pregnant or breastfeeding. 3. planning to become pregnant during the study. 4. irregular menstruations combined with perimenopausal symptoms. 5. known hypersensitivity or allergy to any of the components of the test product, or to the comparator (placebo). 6. use of spermicide contraceptives including spermicidal condom within three days prior to first ip dose. 7. history of complicated cystitis, urgency incontinence, recent pyelonephritis, urological and/or gynaecologist abnormalities, immunocompromised, as judged by the investigator. 8. unstable bowel disorder such as diarrhoea, crohn's disease, ulcerative colitis. -
pain rehabilitation virtual reality (prvr): innovations to enhance mobility in the presence of pain

Conditions: Chronic Pain; Musculoskeletal Pain; Fibromyalgia; Virtual Reality

Summary: the proposed research is a single arm feasibility trial of pain rehabilitation virtual reality (prvr) aimed at measuring feasibility, acceptability and utility of vr as well as changes in physical function and fear for adolescents with chronic musculoskeletal pain. the intervention includes standard physiotherapy treatment including functional goal setting and progressive exercise.


Eligibility criteria:
inclusion criteria: * 10 to 17 years old * musculoskeletal pain (e.g. localized \[back, limb\], diffuse) not due to acute trauma (e.g. active sprain or fracture) * english language proficiency exclusion criteria: * significant cognitive impairment (e.g., brain injury) * significant medical or psychiatric problem that would interfere (e.g. psychosis, suicidality) * presents with a condition that interferes with virtual reality usage (e.g., history of seizure, facial injury precluding safe placement of headset, visual impairment, significant hearing impairment impact ability to follow audio instructions).
validation of a score that predicts residual disease in incidental gallbladder cancer

Conditions: Gallbladder Neoplasm Malignant Primary

Summary: an incidental gallbladder carcinoma is detected in approximately 0.2% of the cholecystectomy specimens removed for presumed benign disease. in patients that meet specific criteria, a surgical re-operation is recommended to treat possible residual tumor disease not treated with the initial cholecystectomy. the presence of residual disease in the re-intervention specimen worsens the prognosis of patient survival, according to several published series. patients with known or high-risk of residual disease may benefit from a specific strategy that would improve patient selection before attempting re-resection. a pathology-based score has been developed but has not been yet validated in an external series of patients. the use of pathological data from the initial cholecystectomy specimen could identify patients at risk of residual disease and aid in selecting a specific therapeutic strategy prior to attempting surgical re-exploration.

* sample size: 30 (minimum). * statistical analysis: populations will be compared with chi-square test or fisher's exact test (categorical variables) and student's t test or mann-whitney u test (continuous variables). a univariate and multivariate logistic regression analysis will be performed to evaluate the predictive factors of residual disease. the kaplan-meier method will be applied for survival analysis and curves will be compared using log-rank test. univariate and multivariate cox proportional hazards ratio will be applied to determine the predictive factors of survival. variables with p values inferior to 0.1 in the univariate analysis will be used to perform the multivariate analysis. statistical significance is defined when p \< 0.5. the statistical program used will be spss version 23.

Eligibility criteria:
inclusion criteria: * all consecutive patients with a diagnosis of incidental gallbladder cancer requesting therapeutic evaluation in the participating hospital centers. exclusion criteria: * all patients with non-incidental gallbladder cancer. * all patients with incomplete or deficient data collection. * patients without a signed informed consent.

Keywords: residual disease risk score
metabolic cost of suspension exercise training (set-uth)

Conditions: Body Composition; Physical Fitness; Energy Expenditure; Resting Metabolic Rate

Summary: in this study, the investigators will be able to estimate the metabolic cost of several foundational suspension training exercises.

suspension exercise training has become a popular cardiovascular training choice in fitness centers and athletic performance enhancement facilities. despite widespread use and growing popularity, little is known about the metabolic demands of such a training method. therefore, the purpose of this study was to quantify the cardiovascular and metabolic cost from various foundational suspension training exercises in order to contribute to a better planning of exercise programs in the real world. ten healthy young adults were assigned to execute six suspension training exercises (acute bout) for 30 and 45 seconds. anthropometric, metabolic, and performance measurements were conducted at baseline. the metabolic cost was estimated from heart rate, blood lactate, resting oxygen uptake, exercise oxygen uptake, and excess post-exercise oxygen consumption measurements using a portable gas analyzer.

Eligibility criteria:
inclusion criteria: * aged between 18 and 35 years * physically active individuals * free of chronic diseases * free of musculoskeletal injuries * nonsmokers exclusion criteria: * musculoskeletal injuries * chronic diseases * use of alcohol, caffeine and any type of ergogenic supplements or medication before (≤6 months) and throughout the study.

Keywords: functional fitness training bodyweight training oxygen consumption resistance training
a phase ii multi-center pilot study of concurrent temozolomide and whole brain irradiation in lung cancer and breast cancer patients with brain metastases

Conditions: Lung Cancer and Breast Cancer Patients With Brain Metastases

Summary: brain metastasis (bm) is among the most feared complications in cancer because even small tumors may cause incapacitating neurologic symptoms. it is observed in more than 50% of patients with lung cancer and 15% to 25% of patients with breast cancer. temozolomide (tmz) is an oral alkylating agent that crosses blood-brain barrier (bbb). this pilot study aims to evaluate the efficacy, safety and tolerability of whole-brain radiotherapy (wbrt) plus concomitant tmz in lung cancer and breast cancer patients with bm.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed lung cancer or breast cancer at primary site * patient with inoperable brain metastases * female or male, ≥ 20 and \< 65 years of age * karnofsky performance status (kps) ≥ 70% * life expectancy ≥ 12 weeks * adequate organ function * willing and able to provide a written informed consent exclusion criteria: * female of childbearing potential\* who is pregnant/lactating or planning to be pregnant * male whose partner is planning to be pregnant * inability to swallow * meningeal carcinomatosis * history of hypersensitivity to iodinated contrast media, temozolomide or any component of the study drugs * prior use of temozolomide * use of systemic chemotherapy within 2 weeks prior to the initiation of study treatment * prior surgery, chemotherapy or radiotherapy for a brain neoplasm * current use of valproic acid * use of any investigational product within 4 weeks prior to the initiation of study treatment * patient with any condition or disease which is considered not suitable for this study by investigator

Keywords: lung cancer and breast cancer patients with brain metastases
writing to alleviate violence exposure for transgender women (wave-tw)

Conditions: PTSD; Depression; Virus, Human Immunodeficiency

Summary: wave - tw (writing to alleviate violence exposure for transgender women living with hiv) is an intervention development study which aims to assess the feasibility and acceptability of a proposed trauma writing and adherence intervention that addresses post-traumatic stress disorder (ptsd) and depressive symptoms, antiretroviral therapy (art) adherence and viral suppression among transgender women.


Eligibility criteria:
inclusion criteria: * living with hiv * age 18 or older * detectable viral load within the past year * transgender female * english speaking * capable of completing and fully understanding the informed consent process and the study procedures * history of trauma/abuse exclusion criteria: * unable to completely and fully understand the consent process and the study procedures. * significant interfering mental health symptoms (e.g., untreated active psychosis, active suicidality with a plan). * engaged in an intervention to address trauma symptoms and adherence within the past year
drug treatment for pathologic gambling disorder

Conditions: Gambling

Summary: this study will establish the best dose of the drug naltrexone to treat patients with pathological gambling disorder (pgd) and severe urge symptoms.

pgd is a prominent and growing social problem. unfortunately, there is no established drug treatment for this disorder. preliminary investigations demonstrate that naltrexone in doses up to 250 mg/day is well tolerated and safe during an 11-week period and may be a viable treatment option for pgd patients with severe urges. the implications of this study extend from pgd to other impulse control disorders, including compulsive shopping, kleptomania, and possibly alcoholism. participants are randomly assigned to receive either naltrexone or placebo for 16 weeks. the responses of men and women are compared to determine whether efficacy is distributed in a male:female ratio analogous to that of the pgd population in the united states. a clinical global impression and a gambling symptom scale are used to assess participants.

Eligibility criteria:
inclusion criteria: * diagnostic and statistical manual iv criteria for pathological gambling disorder * moderate or severe gambling urge assessed by the gambling symptom assessment scale * no psychiatric drug use for 2 weeks or more * score \>= 5 on the south oaks gambling screen * hamilton depression rating scale and anxiety rating score \< 26. an increase (up to 10 points) of the scores is allowed unless the subject shows the risks of suicide. * completion of complete blood count, urinalysis, liver and thyroid function tests, and pregnancy tests, with no evidence of significant lab abnormalities * reliable birth control in women of child-bearing potential

Keywords: impulse control disorders
safety and efficacy of methylprednisolone infiltration in anserine bursitis treatment

Conditions: Bursitis

Summary: to investigate the safety and efficacy of methylprednisolone infiltration in anserine bursitis treatment


Eligibility criteria:
inclusion criteria: * clinical diagnosis of anserine bursitis exclusion criteria: * intraarticular pathology that reflects pain in the medial part of the knee

Keywords: anserine bursitis
methylene blue for cognitive dysfunction in bipolar disorder

Conditions: Bipolar Disorder

Summary: while many bipolar patients treated with mood stabilizing medications experience improvement in their symptoms, some continue to have ongoing difficulties with concentration and memory. the purpose of this study is to look at whether these symptoms can be improved by adding the compound methylene blue to the treatment plan of patients who are already taking lamotrigine. methylene blue is an available 'over the counter medication' in canada. it has been studied in the long-term treatment of mood symptoms in bipolar disorder. several clinical studies done in bipolar disorder report that methylene blue has had positive effects on both cognition and mood. it is important to do further research in this area as we know that, for patients who continue to have ongoing cognitive difficulties, there is no recognized standard of care for bipolar patients who experience these type of deficits.

this is a double blind cross-over study. there are two dose ranges in this study. a cross over design means that some patients will start at one dose range and others with another. about half way through the study, patients will then be switched over to the other dose range. patients partially stabilized on lamotrigine will be randomized to either subtherapeutic (16mg) or therapeutic (200mg) dose of methylene blue. this design is necessary because methylene blue stains urine and thus it is not possible to use a traditional placebo. double-blind means that neither the doctor nor the patient will know which strength of study drug the patient will be on at what point in the study. the study will be conducted in three centres, each recruiting 20 subjects over a two-year period. the duration of the study is 6 months.

Eligibility criteria:
inclusion criteria: * men or women between the ages of 18 and 65 who meet both rdc and dsm-iv criteria for bipolar i or bipolar ii disorder will be recruited. * all subjects will be interviewed using sads interview (40) with added questions as to arrive at dsm-iv diagnoses as well. * the patients will be treated with lamotrigine as their main mood stabilizer. patients recruited for the study will show at least partial response to prophylactic treatment with respect to the mood symptoms. * ham-d (17 item) scores at study entry will be 15 or lower and y mrs scores will be less than 15. exclusion criteria: * patients not able to give informed consent * patients with active substance abuse or dependence or a history of such within the past two years * physical illness, mainly liver and kidney disorders and g-6-pd deficiency * subjects previously treated with methylene blue * pregnant or breast-feeding women * subjects who have had ect within the past two years * patients with known brain injury or loss of consciousness of duration greater than ten minutes * subjects taking concurrent medications that are known to have cognitive effects (eg. beta blockers)

Keywords: methylene blue for cognitive dysfunction in bipolar disorder